A Multicenter, Open-Label, Randomized, Controlled Study to Assess the Antitumor Activity of LNS8801 With and Without Pembrolizumab in Patients With Treatment-Refractory, Unresectable Melanoma
Clinical Trial Grant
Awarded By
Linnaeus Therapeutics, Inc.
Start Date
May 1, 2025
End Date
May 14, 2030
Awarded By
Linnaeus Therapeutics, Inc.
Start Date
May 1, 2025
End Date
May 14, 2030